Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 101 от 222

Набира участници

Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

Overactive Bladder (OAB)

This is a pilot study to assess using validated outcome measures how ingesting pumpkin seed oil extract supports patient bladder function in a United States population.

Начало: 11.04.2025 Край: 01.10.2026 Възраст: от 18 г.

United States Northwestern University NCT06944392

Набира участници Фаза 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Lymphoma, Large B-Cell, Diffuse

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

Начало: 11.04.2025 Край: 16.12.2032 Възраст: от 18 г.

Belgium, Germany, Ireland +6 Merck Sharp & Dohme LLC NCT06890884

Набира участници Фаза 1

Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults

Pulmonary Arterial Hypertension

This is the second single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 15 μg to 30 μg.

Начало: 11.04.2025 Край: 30.06.2026 Възраст: 18–65 г. Лечение

New Zealand Pharmosa Biopharm Inc. NCT06429930

Набира участници

Effect of Untact Upper Extremity Rehabilitation Using Smart Glove for Late Subacute and Chronic Patients With Brain Disorder

Brain Disorder Home Based Rehabilitation

The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Glove by comparing the effects between a group using the home-based Neofect Smart Glove and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.

Начало: 11.04.2025 Край: 31.12.2026 Възраст: 19–85 г.

South Korea Samsung Medical Center NCT06837324

Набира участници Фаза 2

Scar Remodeling after Burn Injury using Adipose-derived Allogeneic Stem Cells (ScarASC)

Hypertrophic scarring.

Trial status: Authorised Change in total observer score of the Danish Patient and Observer Scar Assessment Scale version 3.0., Scar volume and microstructure measured by three-dimensional photography, measured in nano cubic meter., Scar elevation index / scar thickness by ultrasound video sequencing, measured as a ratio and in milli meter., Changes in collagen fiber arrangement., Up- and/or downregulation of biomarkers from punch biopsies., Development of de novo HLA., Histologic assessment of the presence of donor stem cells / DNA., Safety assessment by documenting any adverse events or suspected unexpected serious adverse reactions at every follow-up. Change in total patient score of the Danish Patient and Observer Scar Assessment Scale version 3.0.

Начало: 11.04.2025 Възраст: от 18 г.

Denmark Copenhagen University Hospital 2024-519160-41-00

Набира участници Фаза 1

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Recurrent Multiple Myeloma Refractory Multiple Myeloma

This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). SX-682 works by blocking certain sites on cells that suppress the ability of the immune system to destroy tumor cells. Blocking those specific sites allows other cells of the immune system to become "free" to kill tumor cells. Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells, while hyaluronidase helps to deliver daratumumab to CD38-expressing tumor cells through a subcutaneous injection. Dexamethasone is in a class of medications called corticosteroids. It is known to kill myeloma cells and is also used to reduce inflammation and lower the body's immune response to monoclonal antibodies like dratumumab and help lessen its side effects. Giving SX-682 in combination with carfilzomib, daratumumab-hyaluronidase and dexamethasone may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma

Начало: 10.04.2025 Край: 10.04.2030 Възраст: от 18 г.

United States Roswell Park Cancer Institute NCT06622005

Набира участници Фаза 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

CLL Chronic Lymphocytic Leukemia

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Начало: 10.04.2025 Край: 14.02.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +11 BeOne Medicines NCT06846671

Набира участници

Evaluation of a Novel Auto-Adjusting Positive Airway Pressure Algorithm for the Treatment of Obstructive Sleep Apnea Clinical Study

Obstructive Sleep Apnea

This study aims to assess the effectiveness of an investigational algorithm in the treatment of obstructive sleep apnea.

Начало: 10.04.2025 Край: 01.12.2025 Възраст: от 18 г. Лечение

Australia ResMed NCT06769607

Набира участници Фаза 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Начало: 10.04.2025 Край: 02.12.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 AstraZeneca NCT06868277

Набира участници

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Stroke Transient Ischemic Attack (TIA)

The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.

Начало: 09.04.2025 Край: 01.04.2029 Възраст: 18–89 г.

United States University of Alabama at Birmingham NCT06943586

Набира участници Фаза 2/3

Maralixibat in Patients With Cystic Fibrosis and Constipation

Constipation Chronic Idiopathic Cystic Fibrosis

Chronic constipation is common in children with cystic fibrosis (CF), likely due to impaired chloride channel function that reduces intestinal secretions. Standard osmotic laxatives often provide inadequate relief in this population. Maralixibat is an ileal bile acid transporter inhibitor (IBATi) that increases the amount of bile acids reaching the colon. Bile acids can enhance intestinal secretion, reduce transit time, and soften stool. This study will evaluate whether Maralixibat improves stool consistency in children with CF who experience constipation. We will enroll 20 children with CF and constipation, defined as a Bristol Stool Scale score \4. The secondary objective is to assess changes in ease of defecation using standardized questionnaires.

Начало: 09.04.2025 Край: 30.06.2027 Възраст: 1–18 г.

United States Children's Hospital Los Angeles NCT06413368

Набира участници

PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)

Pharmacogenomic Drug Interaction

It is known that individuals respond differently to the same medicine with some people benefitting, some experiencing no effect and others suffering side-effects or even coming to harm. Some of the differences in response to medications can be explained by our genes. Genes are short sections of DNA. Each individual has over 20,000 different genes. Genes carry instructions for making the proteins needed to build things within the body including the sites where medicines act. Pharmacogenomics is the study of how our genes affect the way our body responds to medications. Doctors can test for gene variations that might put an individual at risk of severe side-effects or mean that they are likely to receive no benefit from a specific medicine. Though not widely available in the NHS, testing allows doctors and patients to chose a different dose or avoid the medicine completely. It is estimated that almost everyone in the population (\>95%) carries at least one gene variation that affects our response to medicines. The PHOENIX study will recruit 4,000 participants who are admitted to hospital or attend an outpatient clinic who require a new drug prescription. The new drug prescription will be one who known pharmacogenomic implications. A cheek (buccal) swab will be taken which can be used to test a large number of genes known to alter the response to medicines. Around half of the participants will be tested immediately whilst the other half will have the test after three months. The results of the test relevant to each patients new prescription will enable the doctor prescribing to determine if any changes to that medicine would be beneficial. Information will be collected about participants quality of life, subsequent admissions to hospital, medication changes and side-effects. An assessment of cost saving to the NHS will also be made.

Начало: 09.04.2025 Край: 30.09.2026 Възраст: от 18 г.

United Kingdom NHS Greater Glasgow and Clyde NCT06907784

Набира участници Фаза 1

A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

Healthy Volunteers Rheumatoid Arthritis Systemic Lupus Erythematosus

The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.

Начало: 09.04.2025 Край: 01.11.2027 Възраст: 18–65 г. Лечение

Australia Capstan Therapeutics NCT06917742

Набира участници Фаза 3

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Начало: 09.04.2025 Край: 09.11.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +23 Merck Sharp & Dohme LLC NCT06824467

Набира участници Фаза 3

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).

Начало: 09.04.2025 Край: 30.05.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +17 Hoffmann-La Roche NCT06790693

Набира участници Фаза 3

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Hypertriglyceridemia

This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133). Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to proceed to randomization per the Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. The subjects must meet all other applicable eligibility criteria prior to enrollment and have an HbA1c results of \

Начало: 09.04.2025 Край: 01.07.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +20 Arrowhead Pharmaceuticals NCT06822790

Набира участници Фаза 1/2

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma Stage IV Lung Cancer AJCC v8

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.

Начало: 08.04.2025 Край: 25.07.2029 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT06287775

Набира участници

ctDNA-MRD Monitoring After Resection in Gastric Cancer

Gastric Cancer

Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.

Начало: 08.04.2025 Край: 30.04.2027 Възраст: от 18 г.

China Peking University NCT06893133

Набира участници Фаза 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

Начало: 08.04.2025 Край: 13.07.2036 Възраст: 10–17 г. Лечение

Australia, Italy, Mexico +7 Celgene NCT06408259

Набира участници

Ovulation Induction With GnRH Analogue or Dual Trigger?

Oncological Disease Fertility Preservation

Most medically assisted procreation (ART) techniques, including oocyte cryopreservation for fertility preservation, involve controlled ovarian stimulation. This procedure uses exogenous hormones, primarily follicle-stimulating hormone (FSH), to promote the development of multiple ovarian follicles in a single menstrual cycle. Once follicles reach a suitable number and size, oocyte retrieval (pick-up) is scheduled after pharmacological ovulation induction. Human chorionic gonadotropin (hCG) has been routinely used for ovulation induction, but a common complication is ovarian hyperstimulation syndrome (OHSS). Studies have shown that in antagonist protocols, using a gonadotropin-releasing hormone agonist (GnRH-a) instead of hCG reduces OHSS risk. However, GnRH-a triggers luteal phase dysfunction, likely due to depletion of pituitary LH reserves and lack of LH-like activity (present in hCG), resulting in lower clinical pregnancy rates and occasionally very low oocyte yield. To maximize oocyte retrieval and minimize OHSS risk, a combined "dual trigger" approach using both GnRH-a and hCG has been proposed, leveraging benefits of both agents. Currently, limited data exist regarding the optimal ovulation induction strategy in oncological patients undergoing fertility preservation via oocyte cryopreservation before gonadotoxic therapy, where maximizing outcomes and minimizing complications is critical. This study aims to compare the number of oocytes retrieved per cycle in oncological patients undergoing fertility preservation with ovulation induced by either GnRH-a alone or dual trigger (GnRH-a + hCG). It will also assess the oocyte retrieval rate (number of oocytes retrieved/number of follicles aspirated), number of mature oocytes, and incidence of moderate OHSS within 7 days post-retrieval in both groups. Additionally, it will explore correlations between serum estradiol (E2) and luteinizing hormone (LH) levels on the trigger day and oocyte yield. Approximately 200 patients aged ≥18 years will be consecutively enrolled over 2 years and 2 months. Retrospective period considered: from January 1, 2023, to the study initiation date. Patients will be assigned by clinicians to one of two groups based on clinical characteristics: Group 1: Ovulation induced with 0.2 mg subcutaneous triptorelin (Decapeptyl®) Group 2: Ovulation induced with 0.2 mg subcutaneous triptorelin plus 1000-5000 IU urinary hCG (Gonasi®) Treatment follows standard clinical practice.

Начало: 07.04.2025 Край: 03.04.2027 Възраст: 18–46 г.

Italy IRCCS Azienda Ospedaliero-Universitaria di Bologna NCT07546136

1 … 99 100 101 102 103 … 222